HUE044263T2 - ANG2-kötõ molekulák - Google Patents

ANG2-kötõ molekulák

Info

Publication number: HUE044263T2
Authority: HU; Hungary
Prior art keywords: ang2; binding molecules; molecules; binding
Prior art date: 2012-03-30

Application number

Other languages

English (en)

Inventor

Eric Borges

Andreas Gschwind

Rene Georg Ott

Marie-Ange Buyse

Joachim Boucneau

Pascal Merchiers

Erik Depla

Frederik Stevenaert

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-30

Filing date

2013-03-27

Publication date

2019-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE044263(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-27 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2019-10-28 Publication of HUE044263T2 publication Critical patent/HUE044263T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

HUE13718796 2012-03-30 2013-03-27 ANG2-kötõ molekulák HUE044263T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12162615		2012-03-30

Publications (1)

Publication Number	Publication Date
HUE044263T2 true HUE044263T2 (hu)	2019-10-28

Family

ID=48190468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE13718796 HUE044263T2 (hu)	2012-03-30	2013-03-27	ANG2-kötõ molekulák

Country Status (27)

Country	Link
US (5)	US20130259859A1 (hu)
EP (1)	EP2831111B1 (hu)
JP (1)	JP5970734B2 (hu)
KR (1)	KR102020255B1 (hu)
CN (1)	CN104321344B (hu)
AU (1)	AU2013241769B2 (hu)
BR (1)	BR112014023415B1 (hu)
CA (1)	CA2865464C (hu)
CL (1)	CL2014002393A1 (hu)
CY (1)	CY1122007T1 (hu)
DK (1)	DK2831111T3 (hu)
EA (1)	EA031182B1 (hu)
ES (1)	ES2729165T3 (hu)
HR (1)	HRP20190817T1 (hu)
HU (1)	HUE044263T2 (hu)
IL (1)	IL234234B (hu)
IN (1)	IN2014DN06904A (hu)
LT (1)	LT2831111T (hu)
MX (1)	MX350248B (hu)
NZ (1)	NZ628584A (hu)
PH (1)	PH12014502179B1 (hu)
PL (1)	PL2831111T3 (hu)
PT (1)	PT2831111T (hu)
RS (1)	RS58732B1 (hu)
SI (1)	SI2831111T1 (hu)
TR (1)	TR201908638T4 (hu)
WO (1)	WO2013144266A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP2017532342A (ja)	2014-10-17	2017-11-02	アムジエン・インコーポレーテツド	眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体
JP7064670B2 (ja) *	2015-03-31	2022-05-11	ソリッソファーマシューティカルズ，インク．	プロテアーゼで切断可能なリンカーを有するペプチド構築体
EP3328886B1 (en) *	2015-07-29	2020-09-16	Allergan, Inc.	Heavy chain only antibodies to ang-2
AU2017343779A1 (en) *	2016-10-13	2019-04-04	Dana-Farber Cancer Institute, Inc.	Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) *	2016-12-26	2020-08-10	기초과학연구원	항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
MX2019014199A (es) *	2017-06-02	2020-01-23	Boehringer Ingelheim Int	Tratamiento de combinacion antineoplasico.
CN108659130B (zh) *	2018-05-28	2021-09-10	长春力太生物技术有限公司	一种抗癌胚抗原纳米抗体及其应用
EP3813880A4 (en)	2018-06-29	2022-07-13	Gensun Biopharma Inc.	ANTAGONISTS OF ANTITUMOR IMMUNE CHECKPOINT REGULATORS
CA3131250A1 (en) *	2019-02-25	2020-09-03	Pharmabcine Inc.	Anti-ang2 antibody and use thereof
US20220185875A1 (en) *	2019-03-18	2022-06-16	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific antibody specifically bound to vegf and ang2
WO2020263312A1 (en)	2019-06-28	2020-12-30	Gensun Biopharma, Inc.	ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN119552875A (zh) *	2020-03-03	2025-03-04	爱普济德生物技术有限公司	适体和其用途
CN111875706B (zh) *	2020-07-16	2021-03-30	广州康盛生物科技股份有限公司	一种抗人IgE蛋白的单域抗体及其应用
US20220389120A1 (en)	2021-06-03	2022-12-08	Gensun Biopharma Inc.	Multispecific antagonists
US20240425575A1 (en) *	2021-09-10	2024-12-26	Soter Biopharma Pte. Ltd	Anti-ang2 antibody, preparation method therefor, and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0656946B2 (en)	1992-08-21	2010-03-31	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US5643755A (en)	1994-10-07	1997-07-01	Regeneron Pharmaceuticals Inc.	Nucleic acid encoding tie-2 ligand
US5814464A (en)	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
EP2316951A1 (en)	2001-01-17	2011-05-04	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
EP1399484B1 (en)	2001-06-28	2010-08-11	Domantis Limited	Dual-specific ligand and its use
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US7205275B2 (en)	2001-10-11	2007-04-17	Amgen Inc.	Methods of treatment using specific binding agents of human angiopoietin-2
AU2003283137B8 (en)	2002-11-08	2010-07-29	Ablynx N.V.	Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
EP1900753B1 (en)	2002-11-08	2017-08-09	Ablynx N.V.	Method of administering therapeutic polypeptides, and polypeptides therefor
EP1687338B1 (en)	2003-11-07	2010-10-20	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
AU2005293752A1 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
CA2595610C (en)	2004-12-21	2013-03-05	Astrazeneca Ab	Antibodies directed to angiopoietin-2 and uses thereof
RU2464276C2 (ru)	2005-05-18	2012-10-20	Аблинкс Н.В.	Улучшенные нанотела против фактора некроза опухоли-альфа
US20080014196A1 (en)	2006-06-06	2008-01-17	Genentech, Inc.	Compositions and methods for modulating vascular development
AU2007285695B2 (en)	2006-08-18	2012-05-24	Ablynx N.V.	Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2121757A2 (en)	2007-02-21	2009-11-25	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
JP2011525476A (ja)	2008-03-05	2011-09-22	アブリンクスエン．ヴェー．	新規の抗原結合二量体複合体、その製造方法及び使用
CN102112155B (zh) *	2008-06-05	2016-08-10	埃博灵克斯股份有限公司	针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
JP5823871B2 (ja) *	2008-12-10	2015-11-25	アブリンクスエン．ヴェー．	血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) *	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2

2013
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja active Active
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh active Active
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en unknown
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en active Active
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt active IP Right Grant
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active Active
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en active Application Filing
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179B1/en unknown
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
2019
- 2019-04-30 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending

Also Published As

Publication number	Publication date
TR201908638T4 (tr)	2019-07-22
CY1122007T1 (el)	2020-10-14
NZ628584A (en)	2016-04-29
PH12014502179A1 (en)	2014-12-10
SI2831111T1 (sl)	2019-06-28
EP2831111B1 (en)	2019-03-20
CN104321344A (zh)	2015-01-28
US20190135907A1 (en)	2019-05-09
IL234234B (en)	2020-06-30
CA2865464A1 (en)	2013-10-03
EP2831111A1 (en)	2015-02-04
LT2831111T (lt)	2019-05-10
JP5970734B2 (ja)	2016-08-17
BR112014023415B1 (pt)	2022-04-12
KR20140146606A (ko)	2014-12-26
MX2014011171A (es)	2015-03-06
PH12014502179B1 (en)	2014-12-10
RS58732B1 (sr)	2019-06-28
BR112014023415A2 (pt)	2017-07-11
CN104321344B (zh)	2017-11-21
HRP20190817T1 (hr)	2019-06-28
WO2013144266A1 (en)	2013-10-03
US20230203146A1 (en)	2023-06-29
MX350248B (es)	2017-08-31
IN2014DN06904A (hu)	2015-05-15
EA201401065A1 (ru)	2015-03-31
AU2013241769B2 (en)	2017-05-11
ES2729165T3 (es)	2019-10-30
CA2865464C (en)	2022-07-12
JP2015516805A (ja)	2015-06-18
US20200207845A1 (en)	2020-07-02
DK2831111T3 (en)	2019-04-29
US20170107281A1 (en)	2017-04-20
US20130259859A1 (en)	2013-10-03
CL2014002393A1 (es)	2015-01-23
KR102020255B1 (ko)	2019-09-10
EA031182B1 (ru)	2018-11-30
PT2831111T (pt)	2019-05-31
PL2831111T3 (pl)	2019-09-30
AU2013241769A1 (en)	2014-08-28

Publication	Publication Date	Title
DK3327112T3 (en)	2020-05-04	Agse-deficient stamme
IL234234B (en)	2020-06-30	2ang binding molecules
DK2830816T3 (en)	2020-02-17	Hidtil ukendt coatingkoncept
AP2015008266A0 (en)	2015-02-28	1L-18 binding molecules
EP2935220A4 (en)	2016-04-27	PERI-carbinol
EP2812698A4 (en)	2015-09-23	TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
EP2834250A4 (de)	2015-10-14	Lithiumsilikate
AU345893S (en)	2012-12-04	Treehouse
GB201212004D0 (en)	2012-08-22	Dynodisc
GB201205681D0 (en)	2012-05-16	Catshield
GB201204748D0 (en)	2012-05-02	Toretear
GB201204316D0 (en)	2012-04-25	Comniview
GB201204245D0 (en)	2012-04-25	MobiKey
GB201204164D0 (en)	2012-04-25	Plugstop
GB201204088D0 (en)	2012-04-18	Tidythatcable
GB201203962D0 (en)	2012-04-18	Locnlatch
GB201203844D0 (en)	2012-04-18	Salvacubo
GB201203777D0 (en)	2012-04-18	Quit-clip
GB201203776D0 (en)	2012-04-18	Sili-m8
GB201203815D0 (en)	2012-04-18	Mini-meals
GB201203808D0 (en)	2012-04-18	MicBooth
GB201203507D0 (en)	2012-04-11	Keynut
GB201203453D0 (en)	2012-04-11	TVtidy
GB201203440D0 (en)	2012-04-11	Blu-seals
GB201203045D0 (en)	2012-04-04	Chrismar